1. Polyfunctionality of the CXCR4/CXCL12 axis in health and disease: Implications for therapeutic interventions in cancer and immune‐mediated diseases
   C. Britton et al, 2021, The FASEB Journal CrossRef
2. NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer
   Yueyue Wang et al, 2018, International Journal of Oncology CrossRef
3. Lycium ruthenicum Murr. anthocyanins inhibit hyperproliferation of synovial fibroblasts from rheumatoid patients and the mechanism study powered by network pharmacology
   Ke Xu et al, 2023, Phytomedicine CrossRef
4. The N-terminal polypeptide derived from vMIP-II exerts its anti-tumor activity in human breast cancer by regulating lncRNA SPRY4-IT1
   Haihua Wu et al, 2018, Bioscience Reports CrossRef
5. Pathogen-derived peptides in drug targeting and its therapeutic approach
   Seok-Jun Mun et al, 2022, Journal of Controlled Release CrossRef
6. Predictive value of expression of the CXCR4/Akt signaling pathway in the peripheral blood for brain glioma
   Xueli Zou, 2024, Revista Romana de Medicina de Laborator CrossRef
7. NLGN3 Upregulates Expression of ADAM10 to Promote the Cleavage of NLGN3 via Activating the LYN Pathway in Human Gliomas
   Ning-Ning Dang et al, 2021, Frontiers in Cell and Developmental Biology CrossRef
8. CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer
   Xiao-Feng Xie et al, 2022, Cancer Letters CrossRef
9. Double-Targeted Knockdown of miR-21 and CXCR4 Inhibits Malignant Glioma Progression by Suppression of the PI3K/AKT and Raf/MEK/ERK Pathways
   Feijiao Liu et al, 2020, BioMed Research International CrossRef
10. Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies
    Alessio Ardizzone et al, 2023, Cells CrossRef